Juvaris Biotherapeutics, Inc. contact ussite map Juvaris In the News Juvaris Technology Juvaris BioTherapeutics Announces License to Colby Pharmaceutical Company for JVRS-100... and CLDC (Cationic Lipid-DNA Complex) Platform for Human Health Juvaris BioTherapeutics Announces Publication of Preclinical Anti-Leukemic Effects of JVRS-100 Immunotherapy Juvaris...

BioTherapeutics, Inc. - Immune system booster and vaccine adjuvant June 2007 Contact us for more information About Us|Technology Platform|Collaborators|News & Presentations|Contact... 2009 Nature Biotechnology; Biotech for your Companion? December 2007 Forbes/Wolfe Emerging Tech Report; Technology Trends to Watch in 2008 December 2007 StartUp Magazine; Juvaris...

information About Us|Technology Platform|Collaborators|News & Presentations|Contact|Site Map|Home Terms of Use|Legal|Site Users Guide 2013 Juvaris BioTherapeutics. 2013 Juvaris BioTherapeutics. ..., worldwide rights to develop and commercialize Juvaris' adjuvanted vaccine and immunotherapy technology in the field of human health. In exchange for the license, Colby will pay to Juvaris... and commercialize Juvaris technology in the field of animal health, in exchange for significant upfront payments, milestone payments and future royalties on product sales. Under the terms...

novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer. The Company's platform technology induces profound immunostimulation via cationic lipid-DNA... Contact us for more information About Us|Technology Platform|Collaborators|News & Presentations|Contact|Site Map|Home Terms of Use|Legal|Site Users Guide 2013 Juvaris BioTherapeutics. 2013 Juvaris BioTherapeutics. ... academic collaborators. The Company also has a worldwide strategic alliance with Bayer HealthCare AG for the use of its technology in the field of animal health. ^ back to top...